Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration

BASEL, Switzerland & PHILADELPHIA–(BUSINESS WIRE)–RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund, who contributed USD 11 million to an earlier seed round. RhyGaze was founded on intellectual property exclusively lic